Charles River Laboratories International, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Birgit Girshick
- Full Time Employees
- 19,700
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 251 Ballardvale Street Wilmington MA United States of America 01887
- IPO Date
- Jun 23, 2000
- CIK
- 0001100682
- Website
- criver.com
- Similar Companies
- Business
- Charles River Laboratories International, Inc. (NYSE: CRL) provides essential drug discovery, non-clinical development, safety assessment, and manufacturing solutions to the pharmaceutical, biotechnology, and medical device industries worldwide. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company operates through three primary segments: Research Models and Services (RMS), which supplies research animal models including genetically modified rodents, preconditioned animals, and related services such as genetic monitoring and vivarium management; Discovery and Safety Assessment (DSA), which delivers early-stage discovery studies for target identification, compound validation, in vivo pharmacology, and comprehensive safety testing encompassing toxicology, pathology, bioanalysis, drug metabolism, pharmacokinetics, and safety pharmacology; and Manufacturing Solutions, which offers in vitro quality control testing for sterile and non-sterile pharmaceuticals and consumer products, specialized biologics testing, avian vaccine services including specific-pathogen-free eggs and chickens, and microbial solutions for endotoxin detection. With facilities spanning the United States, Europe, Canada, Asia Pacific, and other international regions, Charles River supports clients from concept to commercialization, including advanced modalities like cell and gene therapies through its integrated CDMO capabilities. Recent developments include a strategic exploration of collaboration with BioTech Social announced in late 2024 to integrate crowdfunding via the BioTech Funding Portal into its Charles River Incubator Program (CIP) and Cell and Gene Therapy Accelerator Program (CAP), both launched in 2024 to provide regulatory expertise, lab space, and funding pathways for early-stage developers; a $13 million expansion of its microbial solutions facility in Charleston County, South Carolina, in August 2025 to enhance quality control testing capacity; alliances with the Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles in 2025 to advance oncology manufacturing and Phase I clinical trial materials for pediatric solid tumors; renewal of its partnership with the CHDI Foundation to bolster Huntington's disease research; and ongoing portfolio enhancements in plasmid DNA, viral vectors, and cell therapy services to meet rising demand in advanced therapies.
Charles River Laboratories International Inc (CRL) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 70/100
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
Fifth Third Bancorp Buys 6,002 Shares of Charles River Laboratories International, Inc. $CRL
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
LH or CRL: Which Is the Better Value Stock Right Now?
Is This the Right Time to Hold CRL Stock in Your Portfolio?
Achieve Life Sciences: CRL Is Fixable, So I Remain Bullish
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
The Healthcare M&A Wave
Disc Medicine: The CRL Has Created A Cleaner Bull Case
Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More
LH vs. CRL: Which Stock Is the Better Value Option?
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference